Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 612 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: UC - Ulcerative Colitis Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis

NCT00073021
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol 800 mg (mesalamine), Asacol 400 mg (mesalamine)
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 75 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
54
States / cities
Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 23, 2026, 2:21 PM EDT
Active, not recruiting Phase 2 Interventional

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

NCT05588843
View directory record Official record
Conditions
Colitis Ulcerative
Interventions
SAR443122, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Lancaster, California • Atlanta, Georgia • Evanston, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 23, 2026, 2:21 PM EDT
Completed Phase 2Phase 3 Interventional Results available

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

NCT03482635
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Hamden, Connecticut • Miami, Florida • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 23, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

NCT02620046
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn's Disease
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
47
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Wheat Ridge, Colorado + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 23, 2026, 2:21 PM EDT
Not listed No phase listed Observational

Individualized Infiximab Dosing-Proof of Concept Study

NCT02027727
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
No Intervention
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
6 Years to 23 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 23, 2026, 2:21 PM EDT
Completed No phase listed Observational

Fecal Biomarker Study for Patients With Ulcerative Colitis

NCT00780507
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
61
States / cities
Lowell, Arkansas • Anaheim, California • Folsom, California + 56 more
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 23, 2026, 2:21 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

NCT07071519
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
12
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 2:21 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Risankizumab, Vedolizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
74
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 65 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 23, 2026, 2:21 PM EDT
Recruiting Phase 3 Interventional

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07185009
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Duvakitug, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years to 80 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
37
States / cities
Tucson, Arizona • Coronado, California • Murrieta, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 2:21 PM EDT
Completed Not applicable Interventional

Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases

NCT02862132
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Vedolizumab
Drug
Lead sponsor
Shaare Zedek Medical Center
Other
Eligibility
Up to 18 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Hartford, Connecticut • Morristown, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 23, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission

NCT00326209
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Encapsulated Mesalamine Granules (eMG)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
61
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 23, 2026, 2:21 PM EDT
Active, not recruiting Phase 4 Interventional

Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial

NCT04835506
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Infliximab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
16 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 23, 2026, 2:21 PM EDT
Recruiting Phase 2 Interventional

Confirmatory Clinical Study in Active Ulcerative Colitis

NCT07296315
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Low-dose MH002, High-dose MH002, Placebo
Drug
Lead sponsor
MRM Health NV
Industry
Eligibility
16 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Miami, Florida • Orlando, Florida • Palmetto Bay, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

GSK2982772 Study in Subjects With Ulcerative Colitis

NCT02903966
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
GSK2982772, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Moreno Valley, California • San Diego, California • Marrero, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 23, 2026, 2:21 PM EDT
Completed Not applicable Interventional

Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Study in Ulcerative Colitis

NCT05662059
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RAVANS, RAVANS-sham
Device
Lead sponsor
Cala Health, Inc.
Industry
Eligibility
10 Years to 39 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 2:21 PM EDT
Active, not recruiting Phase 2 Interventional

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

NCT06254950
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
TAK-279, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Murrieta, California • Clearwater, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 23, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Wireless Capsule Endoscopy in Ulcerative Colitis

NCT00145808
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Given® Diagnostic System
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 23, 2026, 2:21 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Saffron as Anti Inflammatory Agent In Patients With Inflammatory Bowel Disease

NCT04749576
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
saffron supplement for IBD
Dietary Supplement
Lead sponsor
Howard University
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 23, 2026, 2:21 PM EDT
Not listed Phase 1 Interventional

Pilot Study of a New Medical Food in the Management of Ulcerative Colitis

NCT06116643
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Soluble protein hydrolysate (SPHi)
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 23, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

NCT02171429
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Orlando, Florida • Topeka, Kansas • Mentor, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 23, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis

NCT02762500
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
LYC-30937-EC, Placebo
Drug
Lead sponsor
Lycera Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
26
States / cities
Little Rock, Arkansas • Long Beach, California • Mission Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 23, 2026, 2:21 PM EDT
Recruiting Not applicable Interventional

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

NCT05230173
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease
Interventions
Pragmatic
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
24
States / cities
Scottsdale, Arizona • Irvine, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 23, 2026, 2:21 PM EDT
Recruiting No phase listed Observational

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

NCT04751396
View directory record Official record
Conditions
Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Enteropathic Arthritis, Enteropathic Spondylitis, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis
Interventions
Best Practice, Educational Intervention, Interview, Questionnaire Administration, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 23, 2026, 2:21 PM EDT
Not yet recruiting Not applicable Interventional

VR Therapies for IBD

NCT07590518
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn Disease (CD), Anxiety
Interventions
Distraction VR, VR/AI CBT
Device
Lead sponsor
Brennan Spiegel
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 23, 2026, 2:21 PM EDT